Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Hu Zhou, Xuewen Song, Zengmei Sheng, Feng Zhang, Guocai Wu, Lidong Zhao, ZePing Zhou, Lihong Shou, Lili Chen, Xiaotao Wang, Jian Huang, Rong Fu, Dan Chen, Ruibin Huang, Zongjiu Jiao, Jian Lu, Yajun Ruan, Yu Jiao

Blood (2024) 144 (Supplement 1): 5406.

https://doi.org/10.1182/blood-2024-200074

Published: 2024

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Journal Articles

Machine Learning Approach Identifies a Novel Ferroptosis‐Related Gene Model in Aberrant DNA Methylation for Predicting the Progressive Risk of Primary Myelofibrosis

Bingbing Wen, Jian Huang

Blood (2024) 144 (Supplement 1): 6571.

https://doi.org/10.1182/blood-2024-205500

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Shiwei Hu, Xiudi Yang, Ying Lu, Gang Zhang, Xianghua Lang, Li Huang, Jian Huang

Blood (2024) 144 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2024-205090

Published: 2024

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Min Yang, De Zhou, Jian Huang, Liping Mao, Yinjun Lou, Wanzhuo Xie, Jie Jin

Blood (2024) 144 (Supplement 1): 6076.

https://doi.org/10.1182/blood-2024-210439

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2024-204525

Published: 2024

Journal Articles

A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study

Shiwei Hu, Xiudi Yang, Dijiong Wu, Yi Wang, Xiaoqiong Zhu, Weiying Feng, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2024-203703

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 Inhibits Megakaryopoiesis Differentiation and Proplatelet Biogenesis in Thrombocythemia and Polycythemia Vera

Bingbing Wen, Jiansong Huang, Jian Huang

Blood (2024) 144 (Supplement 1): 6583.

https://doi.org/10.1182/blood-2024-205441

Published: 2024

Journal Articles

Cytogenetic Abnormalities Lead to Poor Prognosis in Patients with Myelofibrosis, Especially Postessential Thrombocythemia Myelofibrosis and Postpolycythemia Vera Myelofibrosis: A Multicenter Retrospective Study

Qiutian Feng, Jian Huang

Blood (2024) 144 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2024-205559

Published: 2024

Journal Articles

Comparing the Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing of Polycythemia Vera and Post-Polycythemia Vera Myelofibrosis Patients

Lingrong Tu, Xiudi Yang, Xiaoqiong Zhu, Ying Lu, Honglan Qian, Jian Huang

Blood (2024) 144 (Supplement 1): 6637.

https://doi.org/10.1182/blood-2024-205374

Published: 2024

Journal Articles

A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients

Shiwei Hu, Xiudi Yang, Xiaoqiong Zhu, Honglan Qian, Ying Lu, Yanxia Han, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2024-204773

Published: 2024

Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Blood (2024) 144 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2024-203533

Published: 2024

Journal Articles

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Blood (2024) 144 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2024-205232

Published: 2024

Journal Articles

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Fang Cheng, Yu Wang, Xin Du, Yu Zhu, Jianyu Weng, Na Xu, Yunfan Yang, Jian Huang, Zhenfang Liu, Hongbo Ren, Huifang Zhao, Yajuan Ke, Weiyan Wu, Huanling Zhu, Qian Jiang, Yanli Zhang, Weiming Li

Blood (2024) 144 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2024-202876

Published: 2024

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing in Pre-Fibrotic Primary Myelofibrosis Patients

Shiwei Hu, Xiudi Yang, Jingjing Zhu, Jian Huang

Blood (2023) 142 (Supplement 1): 1836.

https://doi.org/10.1182/blood-2023-182703

Published: 2023

NARROW

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Machine Learning Approach Identifies a Novel Ferroptosis‐Related Gene Model in Aberrant DNA Methylation for Predicting the Progressive Risk of Primary Myelofibrosis

Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Mitoxantrone Hydrochloride Liposome in Combination with Cytarabine and Venetoclax (MAV) Regimen in Relapsed or Refractory Acute Myeloid Leukemia

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study

A Novel JAK2 Inhibitor OB756 Inhibits Megakaryopoiesis Differentiation and Proplatelet Biogenesis in Thrombocythemia and Polycythemia Vera

Cytogenetic Abnormalities Lead to Poor Prognosis in Patients with Myelofibrosis, Especially Postessential Thrombocythemia Myelofibrosis and Postpolycythemia Vera Myelofibrosis: A Multicenter Retrospective Study

Comparing the Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing of Polycythemia Vera and Post-Polycythemia Vera Myelofibrosis Patients

A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing in Pre-Fibrotic Primary Myelofibrosis Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only